NATERA INC (NTRA)

Natera Larger Than S&P 500 Component Alliant Energy

NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-Raise

The company put up a "robust" beat and raise following an increase in test volume and sales prices in women's health and cancer detection.

Which stocks are moving before the opening bell on Friday?

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The biggest pre-market stock movers are ready to go as we check out all of the hottest news happening on Friday morning!

Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life

Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today.

NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Natera (NASDAQ:NTRA) just reported results for the first quarter of 2024.Natera...

NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q1 2024

NTRA stock results show that Natera beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Which stocks are moving after the closing bell on Thursday?

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Natera Reports First Quarter 2024 Financial Results

NTRA September 20th Options Begin Trading

New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer

Natera to Report its First Quarter 2024 Results on May 9

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

First Week of June 21st Options Trading For Natera (NTRA)

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer

New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease

Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan

Agilent Technologies Stock Getting Closer To Key Technical Benchmark

Agilent Technologies stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 65 to 71.

Natera to Participate in March Investor Conferences